.

SPINRAZA STORIES/ADULTS ON SPINRAZA

These are moments and stories.
These are personal victories.
This is SPINRAZA.

have been treated
with SPINRAZA
worldwide*

there’s someone from almost every age group who has taken SPINRAZA

have been treated
with SPINRAZA*

have been treated with SPINRAZA*

*Based on commercial patients, early access patients, and clinical trial participants through September 2021.
‡Includes clinical trial patients.
‡Pivotal clinical studies of SPINRAZA included patients from 3 days to 16 years of age at first dose, but did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger patients.
§Based on commercial patients in the US (including Puerto Rico) through December 2020.

Hear from adults on SPINRAZA.

More than 3700 adults around the world have been treated with SPINRAZA.* Here are some of their stories.

*Based on commercial patients, early access patients, and clinical trial participants through September 2021.

Lauren // Age 20 // Later-onset SMA

“More than anything, I just wanted to maintain my strength.”

Nicole // Age 45 // Later-onset SMA

“I’m so thankful every day that I get to do what I do.”

IAN // AGE 36 // LATER-ONSET SMA

“Now I feel like I am being proactive and doing something that may help me.”

ROBB // AGE 37 // LATER-ONSET SMA

“Spending time with my granddaughter has been amazing.”

JONNA // AGE 36 // LATER-ONSET SMA

“I’m a wife, mother, nature lover.”

YARIANNA // AGE 30 // LATER-ONSET SMA

“I’ve always had a desire to express myself.”

Find more information about SMA.

ABOUT SMA
EXPLORE SUPPORT

IMPORTANT SAFETY INFORMATION

Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs of these risks. Seek medical attention if unexpected bleeding occurs.

Increased risk of kidney damage, including potentially fatal acute inflammation of the kidney, has been observed after administration of similar medicines. Your healthcare provider should perform urine testing before you start treatment with SPINRAZA and before each dose to monitor for signs of this risk.

The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome.

These are not all of the possible side effects of SPINRAZA. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking SPINRAZA, tell your healthcare provider if you are pregnant or plan to become pregnant.

Please see full Prescribing Information.

This information is not intended to replace discussions with your healthcare provider.

INDICATION

SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.

Stay Connected
Sign up with us to receive the latest news, support information, and upcoming events.

Please enter a valid email address.

Why SPINRAZA
How SPINRAZA Works Later-Onset Studies Early-Onset Study Presymptomatic Study Safety Profile
TAKING SPINRAZA
Getting Started Dosing Find a Treatment Center
SPINRAZA STORIES
Adults on SPINRAZA Children on SPINRAZA
WHAT IS SMA
About SMA
Support & Events
Support and Resources Insurance Support SMA360°™ Events FAQs

©2022 Biogen. All rights reserved.
This site is intended for US residents
aged 18 and older.
SPZ-US-3384 v5